Active, not recruitingPhase 3NCT06079281

Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa

Studying Adult hypophosphatasia

Last synced from ClinicalTrials.gov May 3, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Alexion Pharmaceuticals, Inc.
Intervention: ALXN1850(drug)
Enrollment: 124 enrolled
Eligibility: 12-130 years · All sexes
Timeline: 2024 – 2028

Study locations (30)

Research Site, Indianapolis, Indiana, United States
Research Site, Garden City, New York, United States
Research Site, Durham, North Carolina, United States
Research Site, Columbus, Ohio, United States
Research Site, Nashville, Tennessee, United States
Research Site, Ciudad de Buenos Aires, Argentina
Research Site, Clayton, Australia
Research Site, Herston, Australia
Research Site, Parkville, Australia
Research Site, St Leonards, Australia
Research Site, Belo Horizonte, Brazil
Research Site, Brasília, Brazil
Research Site, Recife, Brazil
Research Site, Salvador, Brazil
Research Site, São Paulo, Brazil
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06079281 on ClinicalTrials.gov

Other trials for Adult hypophosphatasia

Additional recruiting or active studies for the same condition.

See all trials for Adult hypophosphatasia →

← Back to all trials